Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

26.80

+0.89 (3.43%)

Aug 10, 2026, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	717.21	673	560	434	363.33	351.41
Revenue Growth	17.55%	20.18%	29.03%	19.45%	3.39%	29.66%
Gross Profit	595.88	564	483	389	335.01	335.4
Operating Income	-528.17	-535	-536	-569	-648.92	-381.74
Net Income	-585.97	-575	-569	-607	-707.42	-454.03
Earnings Per Share	-5.84	-5.83	-6.29	-8.25	-10.12	-6.70
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Crysvita	187	177	134.71	75.7	42.68	21.42
Dojolvi	101.28	96	88.19	70.63	55.61	39.56
Evkeeza	72.72	59	32.16	3.64	-	-
Mepsevii	37	37	30.35	30.44	20.64	16.04
Crysvita Royalty	318.94	304	274.82	182.65	21.69	17.95
Revenue (Total)	717.21	673	560	434	363.33	351.41

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	292	680	610	577.21	747.76	740.2
Total Debt	0	36	40	43.17	31.59	41.97
Net Cash (Debt)	292	644	570	534.04	716.17	698.23
Net Cash Growth	-35.30%	12.98%	6.73%	-25.43%	2.57%	-39.46%
Net Cash Per Share	2.90	6.53	6.30	7.27	10.24	10.30

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-485	-466	-414	-475	-380.47	-338.7
Capital Expenditures	-4.22	-6	-7	-44	-116.12	-73.09
Free Cash Flow	-489.22	-472	-421	-519	-496.59	-411.79
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	83.08%	83.80%	86.25%	89.63%	92.21%	95.44%
Operating Margin	-73.64%	-79.49%	-95.71%	-131.11%	-178.60%	-108.63%
Pretax Margin	-81.18%	-84.84%	-101.25%	-140.32%	-193.14%	-128.91%
Profit Margin	-81.70%	-85.44%	-101.61%	-139.86%	-194.70%	-129.20%
FCF Margin	-68.21%	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	3.67	3.30	6.95	9.07	8.95	16.59